Brinsupri momentum beats expectations and lifts 2026 guidance sharply

The quarter clearly beat the market’s revenue hurdle. Total revenue reached $425.5 million, about 9% above the published consensus of roughly $389.3 million, with the upside concentrated in Brinsupri.

Brinsupri’s launch is tracking ahead, not merely benefiting from a low bar. The company reported roughly 7,000 new patients starting therapy in Q2, more than 6,300 cumulative prescribers, and a 49% sequential revenue increase; it now expects roughly 7,000 new patients per quarter for the rest of 2026. The resulting guidance move to $1.25 billion–$1.4 billion is the filing’s most important change and represents a meaningful upgrade to the commercial outlook (Brinsupri Updates; Guidance).

ARIKAYCE remains a steady asset rather than an incremental upside surprise. Worldwide revenue grew 8.3%, but U.S. revenue rose only 2.2%; the company is relying on potential U.S. and Japanese label expansions for a larger opportunity. Those regulatory filings and preparations are progress, but the 2026 ARIKAYCE guidance was unchanged and excludes any benefit from possible approvals (ARIKAYCE Updates; Guidance).

The pipeline adds support, but not near-term earnings value. The 12-month TPIP open-label data showed improvements in walking distance, biomarkers, functional class, and risk status, while Phase 3 studies remain on schedule. However, the data were presented in July 2026 and are open-label, so this filing mainly reinforces an already-known thesis rather than creating a fresh clinical catalyst (TPIP Updates; Footnotes). The net read is strongly favorable because the Brinsupri beat and guidance increase materially outweigh stable ARIKAYCE performance and continued pipeline execution risk.